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In specialised cells, the expression of specific tubulin isoforms and their subsequent post-translational modifications 
drive and coordinate unique morphologies and behaviours. The mechanisms by which β1-tubulin, the platelet and 
megakaryocyte (MK) lineage restricted tubulin isoform, drives platelet production and function remains poorly 
understood. We investigated the roles of two key post-translational tubulin polymodifications (polyglutamylation and 
polyglycylation) on these processes using a cohort of thrombocytopenic patients, human induced pluripotent stem cell 
(iPSC) derived MKs, and healthy human donor platelets. We find distinct patterns of polymodification in MKs and 
platelets, mediated by the antagonistic activities of the cell specific expression of Tubulin Tyrosine Ligase Like 
(TTLLs) and Cytosolic Carboxypeptidase (CCP) enzymes. The resulting microtubule patterning spatially regulates 
motor proteins to drive proplatelet formation in megakaryocytes, and the cytoskeletal reorganisation required for 
thrombus formation. This work is the first to show a reversible system of polymodification by which different cell 





























Microtubules are large, cytoskeletal filaments vital to a host of critical functions including cell division, signalling, 
cargo transport, motility, and function1,2. The question of how ubiquitously expressed filaments can facilitate 
complex and highly unique behaviours (such as neurotransmitter release and retinal organisation) has been 
addressed by the concept of the tubulin code3,4. This paradigm accounts for the specialisation of microtubules 
and their organisation by describing a mechanism in which particular cells express lineage restricted isoforms of 
tubulin. These cell specific isoforms are then subject to a series of post-translational modifications (PTMs) which 
alter the mechanical properties of microtubules, and their capacity to recruit accessory proteins (e.g. motor 
proteins)1,2,4,5. 
A host of PTMs have been reported in a range of cell types, including tyrosination, acetylation, glutamylation, 
glycylation, and phosphorylation. The loss of specific tubulin PTMs has been linked to disease and dysfunction in 
motile and non-motile cilia (including respiratory cilia, retinal cells), spermatogenesis, muscular disorders, and 
neurological development1,4,6–11. Despite an increasing understanding of the importance of tubulin PTMs in 
disease, the role of the tubulin code in the generation of blood platelets from their progenitors, megakaryocytes 
(MKs) remains poorly understood. 
Platelets are the smallest component of peripheral blood, and circulate as anucleate cells with an archetypal 
discoid shape maintained by a microtubule marginal band12,13. Antagonistic motor proteins maintain the resting 
state of the marginal band, and during platelet activation a motor dependent mechanism results in sliding which 
extends the marginal band and causes the transition to a spherical shape13–15. 
Conversely megakaryocytes are the largest and rarest haematopoeitic cell of the bone marrow. These cells are 
characteristically large, polyploid cells with unique morphological structures (e.g. the invaginated membrane 
system (IMS)) required to facilitate the production of thousands of blood platelets and packaged within them the 
required pro-thrombotic factors15,16. MKs form long, beaded extensions into the lumen of bone marrow sinusoids - 
where these proplatelet extensions then experience fission under the flow of sinusoidal blood vessels which 
results in the release of barbell shaped pre-platelets and platelets into the blood stream16. 
Both MKs and platelets express a lineage-restricted isoform of β1-tubulin encoded by the gene TUBB117. In 
humans, TUBB1 mutations have been shown to result in impaired platelet production, with a resulting 
macrothrombocytopenia18,19. More recently, a C-terminal truncation of β1-tubulin has been shown to cause a 
macrothrombocytopenia, suggesting that C-terminal modifications may be drivers of protein function and 
causative of the disease phenotype observed20. 
While the loss of β1-tubulin is known to result in macrothrombocytopenia, the mechanisms by which this isoform 
of tubulin effects the dramatically different cytoskeletal behaviours of platelets and MKs remains poorly 
understood. In the context of the tubulin code, MKs and platelets present a particularly interesting model. Both 
cells express β1-tubulin, but undergo markedly different cytoskeletal changes. To date, acetylation and 
tyrosination have been the PTMs primarily reported in MKs and platelets, however neither modification is specific 
to the C-terminal tail encoded by TUBB1. Fiore et al. show that a C-terminal truncation of β1-tubulin phenocopies 
the complete loss of the protein20. We therefore hypothesise that PTMs specific to the C-terminus of TUBB1 are 
required for the complex morphological rearrangements required for both MK and platelet function. 
The C-terminal tail of β1 tubulin is particularly rich in glutamate residues which are often targeted for two key 
PTMs implicated in human disease. Polyglutamylation and polyglycylation are PTMs which target glutamate 
residues on both tubulin subunits (α and β) and result in the addition of glutamate or glycine residues 
respectively1,2,21. As both PTMs target the same residue they are together referred to as polymodification. 
Polymodification has been observed in microtubules in centrioles, axenomes, neuronal outgrowths, and mitotic 
spindles1,2. 
To date polyglycylation has not been reported in MKs or platelets. Recently Van Dijk et al. reported on the 
polyglutamylation of β1 tubulin downstream of the integrin α2bβ3  in a CHO cell line engineered to express 
TUBB1, murine MKs, and platelets spread on fibrinogen22. In this work, we report the effects of the loss of the C-
terminus of β1-tubulin in patients with rare TUBB1 variants linked to the low platelet counts. Using induced 
pluripotent stem cell (iPSC) derived MKs and CRISPR knockout, we report a mechanism of polymodification 
which distinctly patterns β1-tubulin in MKs and platelets to spatially co-ordinate key motors. We describe the 
graded, cell specific expression of enzymes which mediate this, and finally report a novel gene, TTLL10, which is 




Study Approval.  
Whole blood was obtained for each experiment from healthy volunteers under the University of Birmingham’s 
ERN 11-0175 license ’The regulation of activation of platelets’. The Genotyping and Phenotyping of Platelets 
(GAPP) study was approved by the National Research Ethics Service Committee West Midlands – Edgbaston 
(REC reference 06/MRE07/36). Participants gave written informed consent in compliance with the Declaration of 
Helsinki. The GAPP study is included in the National Institute for Health Research Non-Malignant Haematology 
study portfolio (ID 9858), and registered at ISRCTN (http://www.isrctn.org) as ISRCTN77951167. 
 
Whole exome sequencing (WES).  
To identify the possible causative variants in these families we sequenced the whole exome of the affected 
individuals with the SureSelect human All Exon 50 Mb kit (Agilent Technologies) and sequenced on the HiSeq 
2500 (Illumina) with 100 bp paired-end reads. 
 
Stem Cell Culture and iPSC MK differentiation.  
Gibco human episomal induced pluripotent stem cell line was purchased from Thermo Scientific and cultured on 
Geltrex basement membrane in StemFlex medium (Thermo Scientific). iPSC differentiation to mature, proplatelet 
forming megakaryocytes was performed using a protocol based on work published by Feng et al.23 The IDT Alt-
R®RNP system was used to target and knock-out TUBB1. iPSC transfection was performed using Lipofectamine 
Stem (Life Technologies) according to manufacturer instructions. 
 
TUBB1 Homology Modelling.  
Homology models of TUBB1 WT and variants were made using SWISS MODEL software24–27, using the solved 
TUBB3 heterodimer as a template PDB: 5IJ028. TUBB1 and TUBB3 share approximately 80% sequence identity, 
and the model created corresponds to residues 1-425 of TUBB1. (Note that the C-terminal tail of TUBB1 is not 
presented in this model as there is no known or homologous structure available for this highly divergent 
sequence. The C-terminal portion of this model is used only as a means to visualise the effect of genetic 
variations on the C-terminal tail of TubB1). 
 
Statistics.  
Statistical analysis was performed using GraphPad PRISM 7. Specifics of each test are detailed in the figure 
legends of the relevant figures. P values below 0.05 were considered significant. 
 
Detailed Materials and Methods can be seen in the Supplementary section.
Results 
 
Identification and initial characterisation of TUBB1 variants in patients with inherited thrombocytopenia 
and platelet dysfunction.  
Using whole exome sequencing and Congenica Clinical genetic variant interpretation software29 of patients 
recruited to the GAPP (Genotyping and Phenotyping of Platelets) study, two C-terminal TUBB1 variants were 
identified in unrelated families presenting with macrothrombocytopenia (Figures 1 A, S1). Affected individuals in 
Family A were found to be heterozygous for an arginine to tryptophan amino acid substitution (c.1075C>T, 
p.R359W) in TUBB1. Individuals in this family also carry a GFI1B variant (p.Cys168Phe). Variants in both genes 
have been linked to thrombocytopenia, however only individuals A:1 and A:3 (carrying TUBB1 variants), present 
with a macrothrombocytopenia (107 and 85 x 109/L respectively). Individual A:2 carries the GFI1B variant but is 
WT for TUBB1 and presents with a normal platelet count (221 x 109/L). Individuals A:1 and A:3 also present with 
significantly higher immature platelet fractions (IPFs) and mean platelet volumes (MPVs) when compared to their 
TUBB1 WT relatives (53.5% and 55.1% compared to 25.5%, MPV for A:1 and A:3 too large for measurement). 
This variation in count, IPF and platelet morphology in individuals with the TUBB1 R359W variant may suggest 
that the TUBB1 variant is linked to the macrothrombocytopenia observed. 
Family/patient B was an elderly gentleman (now deceased) with a G insertion and subsequent frameshift 
truncation of the β1-tubulin protein 19 amino acids from the site of insertion (c.1080insG, p.L361Afs*19) 30,31. This 
patient had a severe thrombocytopenia with a platelet count of 11 x 109/L and an MPV above 13.4 (Figure 1B). At 
the time of study, IPF measurement was unavailable. 
p.L361Afs*19 is absent in the latest version of the gnomad database (accessed October 2020), while p.R359W is 
a rare variant with a frequency of 6.78 x 10-3 (gnomad accessed October 2020) with a significant pathogenicity 
prediction score of 25.4 using CADD (Combined Annotation Dependent Depletion), where a score of greater or 
equal to 20 indicates the 1% most deleterious sequence variants in the genome. Both variants were analysed 
using in silico bioinformatic tools and were scored as ‘uncertain significance’ based on the current ACMG 
guidelines32 (Figure S1). Both TUBB1 variants are positioned towards the C-terminal region of β1-tubulin as 
indicated in figures 1 C and D. This region is positioned away from the dimer interface with α-tubulin, and the 
glutamate rich C-terminal tail, not present in the model, is an established site for PTM (Figure 1 C,D)1. Both 
affected TUBB1 sequence variants are highly conserved in mammals (Figure 1 E). R359 is found within a loop 
region towards the C-terminus of tubulin, and we predict mutating this residue would not cause dramatic 
misfolding within the protein secondary structure. R359 does form direct polar contacts with the N-terminal helix 
and removing this contact through the sequence variant to the hydrophobic tryptophan may result in minor 
structural changes to the connected C-terminal regions, potentially affecting PTM or interactions with critical 
microtubule accessory proteins (MAPs) (Figure 1 C, D). Similarly, the G insertion and subsequent frameshift 
effectively deletes the C-terminus of the protein and would thus, if the protein folds correctly, result in effects 
similar, or more extreme, to the substitution of R359. 
Patient B demonstrated a significant reduction in surface P-selectin expression and fibrinogen binding by flow 
cytometry in response to all agonists tested (Figure S1). Family A showed no change in the levels of surface 
receptor expression, but weak P-selectin and fibrinogen responses when activated with a low concentration ADP, 
CRP, and PAR-1, suggesting a mild functional defect (Figure S1 C,). Patient B also showed marked reduced 
expression of P-selectin and fibrinogen uptake in response to the same activation agonists (Figure S1 D, E).  
Patients with C-terminal variants in this study and others previously reported by Fiore et al. present with a 
macrothrombocytopenia also found in individuals with a complete loss of the β1-tubulin, suggesting that the C-
terminal tail is likely critical to the function of TUBB1 in the roles of microtubules in MKs and platelets18–20. As this 
C-terminal tail is rich in glutamate residues which are often targeted for polymodification, we began to investigate 
the polymodification of β1-tubulin. 
 
C-terminal variants of β1-tubulin fold correctly and demonstrate a reduction in polymodification.  
First, we investigated the effects of the two patient variants (p.R359W and p.L361Afs*19) on the folding and 
potential polymodification of β1 tubulin. We designed, generated, and validated a β1 tubulin-mApple fusion 
construct (Figure S2). This plasmid was further mutated to harbour each of the patient variants (p.R359W and 
p.L361Afs*19), and an artificial C-terminal truncation which specifically deletes the glutamate rich C-terminal tail 
(Figures S2, 2A). The WT β1 tubulin construct was transfected into Hek293T cells and co-stained for 
polyglutamylated and polyglycylated tubulin specifically. Transfected cells are exclusively positive for both 
residues indicating that β1 tubulin is indeed polymodified (Figure 2B). Expression of each of the mutated 
constructs show that both patient variants and the C-terminal truncation fold correctly (Figure 2C). Furthermore 
each of the results in a consistent and significant reduction in polymodification (Figure 2D). This data indicates 
that both patient variants result in a correctly folded β1 tubulin which has a similar effect to a truncation of the C-
terminus, and is further supported by western blotting of mutant constructs (Figure S3) which show a significant 
reduction in polymodification. 
 
iPSC-derived proplatelet forming MKs are both polyglycylated and polyglutamylated.  
The tubulin code posits that a highly lineage and species specific expression of modifying enzymes mediates cell 
specific PTMs. While our transfection data successfully indicates that β1-tubulin is indeed polymodified, and that 
each of our patient genetic variants result in the expression of a functional β1-tubulin with a C-terminal truncation, 
data from both human MKs and platelets is needed to dissect the role of polymodification in these cells. 
To date, polyglycylation has not been reported in either platelets or megakaryocytes. Polyglutamylation has 
recently been reported in a modified CHO cell line and human platelets. To investigate polymodification in human 
megakaryocytes, we adapted a directed differentiation protocol previously reported by Feng et al. to generate 
large populations of mature, proplatelet forming cells (Figure S4). iPSC-MK were stained for CD42b as a marker 
for mature, and hence TUBB1 expressing, MKs, and both polyglutamylated and polyglycylated tubulin. CD42b+ 
cells were found to be positive for both polyglutamylated tubulin and polyglycylated tubulin (Figure 3A), while 
neighbouring cells in the sample negative for CD42b did not demonstrate these polymodifications (Figure 3B). 
Across multiple differentiations we consistently yielded a purity of ~50-60% CD42b+ cells (Figure 3C), which on 
analysis are positive for both polyglutamylated and polyglycylated tubulin (Figure 3D). Finally, 100% of proplatelet 
forming cells observed across replicates were positive for both polymodifications (Figure 3E), and this was further 
confirmed by western blot (Figure 3F). 
 
CRISPR knockout of β1-tubulin results in a complete loss of proplatelet formation.  
To date, the loss of TUBB1 has not been studied in human MKs. We generated an iPSC line with a CRISPR 
mediated bi-allelic loss of function mutation in the N-terminus of the coding region of TUBB1 (Figure 3G, S5). The 
mutation of the TUBB1 start codon on both alleles results in a complete loss of expression (absence of T2 band 
in Figure 3H) and proplatelet formation in vitro (Figure 3I, J – right panel). Unfortunately, our attempts to generate 
C-terminal truncations through CRISPR in iPSC-MKs were unsuccessful as multiple guides targeting the 3’ end of 
the TUBB1 gene failed to cleave the genomic sequence. Interestingly while TUBB1 knock-out clones stain 
positively for polyglutamylated and polyglycylated tubulin, the distribution of these residues is disturbed when 
compared to WT platelet forming iPSC-MKs (Figure 3K). While polyglycylated and polyglutamylated residues 
form a distinct peripheral band around WT MKs as shown in figure 3K, the knockout cells demonstrate a diffuse 
tubulin staining (evidenced by line profiles in Figure S7). Figure 3L shows quantification of this staining whereby 
wildtype iPSC-Mks display higher mean intensity than knockout constructs in polyglycylated tubulin, however no 
significant quantitative change in polyglutamylation was observed. This is the first data demonstrating the effects 
of the loss of TUBB1 expression in human MKs.  
 
Platelets demonstrate a different pattern of polymodification.  
We hypothesised that the β1-tubulin polymodifications evident in MKs might be differently regulated between 
resting and activated platelets. We therefore compared immunofluorescence staining of polyglutamylated and 
polyglycylated tubulin between resting platelets and cells spread on fibrinogen and collagen. 
Resting platelets demonstrate polyglutamylated tubulin which partially colocalises with the β1-tubulin marginal 
band unlike MKs which demonstrate extensive polyglycylation in proplatelet forming cells (Figure 4A). On 
fibrinogen and collagen spreading, polyglutamylation is evident, notably at the marginal band of spreading cells 
on fibrinogen (Figure 4B). A lack of polyglycylation is consistent in both resting and activated platelets. Western 
blotting of resting platelets and cells activated through stimulation by CRP over time does not show an increase in 
the total amount of polyglutamylated tubulin (Figure 4C). An increase in the co-localisation between β1-tubulin 
and polyglutamylated residues suggests that while the total polyglutamylation of platelets remains unchanged 
through activation, the distribution of these residues is altered (Figure 4D). We confirmed the polyglutamylation 
(and loss of polyglycylation) in microthrombi generated by CRP stimulation (Figure 4E, F, G). This data shows 
that while polyglutamylation and re evident in platelet producing iPSC-MKs, polyglycylation is completely lost in 
mature platelets. This is the first evidence of a system whereby these competitive polymodifications are 
dramatically altered between the ’parent’ and terminal cell, suggesting markedly different roles for these residues 
in mediating the function and activity of β1 tubulin. Acetylation and tyrosination have been previously reported in 
platelets, however their role in maintaining the marginal band and/or driving morphological change on platelet 
activation remains unclear13. To determine whether the polyglutamylation of the marginal band we observe thus 
far coincides with these PTMs, we performed a time course of spreading on fibrinogen to determine whether 
there is an equivalent increase in either acetylation or tyrosination of the marginal band. Interestingly, we find a 
significant decrease in acetylation and tyrosination over time (between 0 and 10 minutes), while a notable 
polyglutamylation of the marginal band is evident from the earliest time point (10 minutes spreading on 
fibrinogen) and does not decrease (Figure 4F,G). 
 
Platelet and MK polymodifications regulate motor protein localisation to drive both proplatelet formation 
and platelet shape change on activation.  
Polyglutamylation has been reported as a means by which motor protein processivity is regulated, and like in 
neuronal cells, MK proplatelet formation is known to be driven by a mechanism of dynein mediated proplatelet 
sliding33. Similarly, the antagonistic movement of dynein and kinesin are known to maintain the marginal band in 
resting platelets13. 
To test if polymodification affects the spatial distribution of motors, we performed a time course of platelet 
spreading on fibrinogen and measured co-localisation between polyglutamylated tubulin and dynein (DNAL1 - 
axonemal light chain 1). We observe a loss of co-localisation between dynein and polyglutamylated residues 
upon platelet spreading (Figure 5A, B). Interestingly, axonemal dynein is also localised towards the leading edge 
of spread platelets (Figure 5A). This data suggests that the increased polyglutamylation of the marginal band 
observed on platelet spreading drives an outward movement of axonemal dynein. To investigate the role of 
axonemal dynein specifically in this process, we also stained spreading platelets for cytoplasmic dynein and 
observe a central distribution, suggesting an alternative role for cytoplasmic dynein in platelets (Figure S6). 
 
The loss of co-localisation between polyglutamylated tubulin and dynein was confirmed on both collagen and 
fibrinogen spread platelets (5C, E). This spatial relationship was also observed between polyglutamylated tubulin 
and kinesin-1, a motor protein recently reported to be important in platelet secretion on platelet spreading (Figure 
5 D, F)34. 
This data suggests that polyglutamylated tubulin is involved in localising motor proteins during platelet activation 
and spreading. The actions of kinesin and dynein are known to be critical to driving platelet shape change on 
activation, and this work is consistent with previous reports of polyglutamylated tubulin altering the processivity of 
motors in axons. 
We then investigated the role of these polymodifications on the distribution of motors in iPSC-MKs. In proplatelet 
extensions axonemal dynein and kinesin-1 are both evident along the length of the proplatelet shaft (Figure 5G). 
β1-tubulin knockout cells show no proplatelet formation, and a significant reduction in the co-localisation of dynein 
with polyglutamyulated residues when compared to WT iPSC-MKs (Figure 5H,I). No significant change in the 
colocalisation of these residues with kinesin-1 is observed between WT and knockout iPSC-MKs (Figure 5J). 
 
MK and platelet polymodification is regulated through the expression of both modifying and reversing 
enzymes. 
We hypothesise that the expression of cell specific subsets of effecting (TTLL) and reversing (CCP) enzymes are 
required to achieve the distinctive polymodification we observe in MKs and platelets. We designed a qRT-PCR 
panel to interrogate the expression of the 13 known mammalian TTLLs and 6 CCPs. We generated RNA from 
iPSC-MKs at different stages of maturation (Figures 6A, S4A). Day 1 (d1) cells are representative of a pool of 
haematopoeitic stem cells (HSCs) and MK progenitors, while day 5 (d5) cells are comprised of 60% CD41/42b+ 
cells (Figures 6A , S4 E). Finally, day 5 cells treated with heparin to induce proplatelet formation (d5 + Hep) were 
used to interrogate whether there is any specific up-regulation of TTLLs and/or CCPs on proplatelet formation 
(Figures 6A, S4D). 
GAPDH housekeeping controls for each of the 3 samples (d1, d5, d5+Hep) show equivalent amplification of the 
housekeeping control, while results for TTLL family proteins show a number of enzymes expressed at different 
levels across the maturation of these cells (Figure 6B,C). Candidate TTLLs observed in the initial endpoint PCR 
were taken forward for quantification across replicates generated from multiple differentiations (Figure 6C, D). We 
find a significantly increased expression of TTLL1, TTLL2, TTLL4, and TTLL10 on proplatelet formation in cells 
treated with heparin (** p = 0.0081, * p = 0.0105, * p = 0.0260, *** p = 0.0004 respectively) (Figure 6D). CCP 
family enzymes were also found to be expressed in maturing MKs, notably CCP1, 3, 4, 5, and 6 (Figure 6E), with 
CCP4 and 6 up-regulated on proplatelet production (* p = 0.0130, *** p = 0.0009) (Figure 6F). 
To investigate TTLL and CCP expression in platelets, we repeated this panel on RNA extracted from resting and 
CRP stimulated donor platelets. We found that none of the TTLLs and CCPs observed in iPSC MKs were 
consistently expressed across donors with the exception of TTLL7, a known polyglutamylase (Figure 6I, complete 
gel in figure S10)35. No differences between resting and activated platelets were observed (Figure 6I). This data 
shows a markedly different pattern of TTLL and CCP expression in both MKs and platelets, correlating with the 
observed differences in polymodification. 
 
TTLL10 variants maybe associated with moderate to severe bleeding in 3 unrelated families.  
Our qRT-PCR screen reveals that a number of TTLL and CCPs are up-regulated during the process of platelet 
production, including the polyglycylase TTLL10. Whole exome sequencing data from patients recruited to the 
GAPP study identified 3 unrelated families with rare and novel variants in the TTLL10 gene (Figure 6J, figure 
S12, 13). Extensive in silico analysis was undertaken on the TTLL10 variants which were predicted as ‘uncertain 
significance’ using current ACMG guidelines (Figure S12, 13)32. Two of the three variants result in frameshifts 
towards the N-terminus of the protein, preceding the ATP binding region (p.Pro15Argfs*38 (novel) and 
p.Val249Glyfs*57 (frequency 2.15 x 10-3) (Figure 6J). The final family has a missense p.Arg340Trp variant (3.34x 
10≠5 frequency). 
All three families report normal platelet counts, aggregation and secretion, and present an established history of 
moderate to severe bleeding, including cutaneous bruising and menorrhagia (Figure 6K). Family A demonstrated 
a consistently high MPV (normal ranges Mean Platelet Volume (fL) (7.83-10.5), while families B and C do not. 
Interestingly, one of the patients (A 1:1) was re-recruited, and on platelet spreading on fibrinogen coated 
coverslips we observed a marked increase in platelet area compared to controls when imaged using widefield 




We hypothesised that a system of polymodification (polyglutamylation and polyglycylation) targeting the glutamate 
rich C-terminus of β1 tubulin isoform and analogous to similar PTMs demonstrated in cilia and neuronal cells, is a 
likely mechanism by which the interactions of β1 tubulin with key motors are regulated in both MKs and platelets. 
We report that mature and proplatelet forming CD42b+ iPSC-MKs demonstrate both polyglutamylation and 
polyglycylation (polymodification). We observe a markedly different distribution of these PTMs in the resting 
platelet, where polyglycylation is lost and polyglutamylation is partially co-localised to the marginal band. On 
platelet activation, we observe a marked change in the localisation of polyglutamylation specific to the marginal 
band. In iPSC-MKs with a CRISPR knockout of TUBB1, we see a complete loss of proplatelet formation and lose 
the distinct reorganisation of polyglutamylated and polyglycylated tubulin around the periphery of MKs as seen in 
WT cells. 
MK proplatelet extensions are known to be driven by a system of dynein mediated microtubule sliding, while the 
marginal band in a resting platelet has been shown to be maintained by the antagonistic movement of dynein and 
kinesin13,14,36. Interestingly, polyglutamylation has been reported as a mechanism of altering motor protein 
processivity, with in vitro assays suggesting that polyglutamylation of β1 tubulin isoforms like TUBB1 and TUBB3 
accelerates these motors28. We show a significant effect of polyglutamylation on the spatial localisation of dynein 
and kinesin, supporting in vitro assays which suggest that polyglutamylation is an accelerator of motor proteins. 
We report two unrelated patient families with rare TUBB1 C-terminal variants (an R359W missense and a 
L361Afs*19 frameshift linked to macrothrombocytopenia). Interestingly within family A, a second genetic variant in 
the GFI1B gene, which directly affects the TUBB1 promoter is observed. Individuals within family A positive for the 
GFI1B variant but WT for TUBB1 have normal platelet counts and a milder increase in MPV and IPF, indicating 
that the macrothrombocytopenia within the family is possibly linked to the TUBB1 variant, but suggesting a 
potential additive role for the GFI1B variant which is a focus for future study. Both the clinical phenotype and 
laboratory investigations points to variable expressivity of the 2 genetic variants contributing to the overall 
phenotypes observed. 
We go on to show through the expression of these variants in Hek293T cells that each variant results in a 
dysfunctional β1 tubulin protein which is most likely to mirror the effects of a C-terminal truncation. 
The system of polymodification evidenced in iPSC-MKs is analogous to the PTM of ciliated cells, and so we 
reasoned that axonemal dynein, an isoform of the motor exclusive to axonemes, may play a role in both platelet 
formation and activation6,37,38. We find evidence of axonemal dynein on both proplatelet extensions and at the 
leading edge of spreading platelets. To our knowledge this is the first evidence of a functional role of axonemal 
dynein outside of classical ciliated structures. In our TUBB1 knockout MKs, we observe a decrease in the 
colocalisation of dynein to polyglutamyulated tubulin, suggesting that the loss of proplatelet formation observed in 
these cells is due to a dysregulation of the dynein-mediated microtubule sliding known to drive the elongation of 
the proplatelet shaft39. The similarlities between flagella and MK proplatelet extensions have been discussed 
previously, Italiano et al. observe structures similar to flagella in taxol treated MKs, an idea which led to the 
microtubule telescoping experiment reported by Patel et al. and Italiano et al. 39,40. 
Our data suggests a tightly regulated, reversible system of polymodification which must be mediated by the cell 
specific expression of TTLLs and CCPs. Our expression profiles show a number of TTLLs and CCPs are 
expressed by MKs, while only the polyglutamylase TTLL7 is expressed by platelets consistent with the different 
patterns of polymodification oberved in these cells. In MKs we find expression of two TTLLs known to be involved 
in glycylation - the initiase TTLL3 and the elongase TTLL10, with a significant increase in the expression of 
TTLL10 on platelet production. Our findings support a role of TTLL10 as a polyglycylase on co-expression with 
TTLL3 as reported by Ikegami et al. in cell lines through co-transfection experiments. Finally, we report a novel 
gene, TTLL10, in three unrelated families with excessive bleeding. 
We identify 3 unrelated families with TTLL10 variants which result in an increase in an established history of 
bleeding which provides an invaluable insight to the potential role of polyglycylation in the context of platelet 
production and function. Our data shows that both TTLL3 and TTLL10 are expressed in platelet producing MKs. 
Our patient cohort do not lose TTLL3 function, and as such the action of TTLL3 as an initiase will occupy 
glutamate residues which would otherwise be polyglutamylated. In these patients we likely see a loss of 
polyglycylation, but no coincident increase in polyglutamylation due to the normal function of the initiase (TTLL3). 
As polyglutamylation and monoglycylation are unaffected, platelet counts (and production) are normal, however, 
affected individuals appear to have an increased platelet volume and bleeding, suggesting a role for the extended 
glycine tail in regulating platelet size, with a downstream effect on the ability of platelets to prevent bleeding. 
Patel et al. describe a system by which continuous polymerisation is key to the dynein mediated sliding required 
for platelet production39. This work, alongside reports of tyrosination, acetylation, and polyglutamylation in different 
MK models, suggests that tubulin PTMs are likely part of a highly dynamic system in which polymerising 
microtubules are subject to modifications which coordinate platelet production and packaging. Future work will 
interrogate the interplay between different PTMs, and how they fit into a highly dynamic landscape of MT 
polymerisation and function. Indeed, in our KO TUBB1 cells we do not observe a complete loss of 
polymodification, suggesting that compensatory mechanisms which target other isoforms of tubulin may come into 
play. There is likely a more extensive effect on the expression of tubulins and their interplay with other cytoskeletal 
proteins which should be a focus of future work. Similarly, the role of these PTMs will need to be further validated 
in primary human CD34 derived MKs.  
This work supports the paradigm of a ’tubulin code’ and the importance of microtubule patterning in healthy, and 
thus diseased, MKs and platelets. We provide novel insights into the mechanisms by which β1 tubulin functions in 
these unique cells. 
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Figure 1. Candidate TUBB1 variants and their hypothesised effect on the C-terminus of β1-tubulin. (A, B) Two 
unrelated families were identified as carrying genetic variations in the TUBB1 gene within 6 base pairs of one another. 
The first, family A, is comprised of 3 individuals, two of whom carry an Arginine to Tryptophan (p.R359W) coding 
variant. Interestingly, all 3 individuals in family A harbour an additional GFI1B variant. However, the individuals with 
the reported TUBB1 variant (A:1 and A:3) present with a macrothrombocytopenia and high IPF, while the patient 
without the R359W TUBB1 variant presented with a normal platelet count. The second family is comprised of a single 
individual, recently deceased, with a frameshift variant 6 base pairs from the missense change reported in family A. In 
this individual’s case, the insertion of a guanine nucleotide results in a frameshift with a premature stop codon 19 
amino acids from the leucine to alanine change. Platelet count normal range 147 - 327 x 109/L, (n = 40), MPV normal 
range 7.8 - 12.69 fL (n = 40), IPF normal range 1.3 - 10.8% (n = 40). (C) The C-terminal tail is downstream of both 
genetic variants in these families, and projects away from the dimer:dimer interface. The C-terminal sequence of 
TUBB1 is rich in glutamate residues which can be targeted for polymodification. (D) Based on homology modelling of 
TUBB1, we predict that the missense variant reported in family A is likely to affect the fold of the C-terminal tail, while 
the frameshift causes a truncation of this region. (Black arrows indicating the position of the R359 residue). (E) The 
arginine residue substitution in family A is highly conserved across species, as are sequences adjacent to the 
frameshift in patient B. 
 
Figure 2. Cells expressing WT and mutated β1-tubulin demonstrate C-terminal polymodification. (A) Constructs 
carrying WT, patient variants (p.R359W and p.L361Afs*19), and a C-terminal tail truncation of β1-tubulin fused to the 
fluorescent reporter mApple at the N-terminus were designed and cloned. (B) The WT construct was first transfected 
into Hek293T cells, which were then fixed and immunostained for polyglutamylated and polyglycylated tubulin 
residues specifically (C,D) A comparison of the WT and mutated constructs show a reduction in polyglutamylation and 
polyglycylation in each mutant when compared to the WT. (n = 3 independent differentiations, S.D. plotted on graphs. 
2-way ANOVA with multiple comparisons performed to establish significance.) 
 
Figure 3. Mature, proplatelet forming iPSC-MKs are both polyglutamylated and polyglycylated. TubB1 knockout iPSC-
MKs do not form proplatelets and demonstrate disordered polymodified tubulin. (A) iPSC-MKs co-stained for CD42 
and polyglycylated or polyglutamylated tubulin show that these cells are positive for both polymodifications. Both 
polyglutamylated and polyglycylated tubulin are evident in proplatelet extensions, including nascent platelet swellings 
on the proplatelet shaft. (B) Neighbouring CD42b- cells are negative for both polymodifications (indicated by red 
arrows). (C,D) Approximately 50-60% of cells in multiple differentiations are CD42b+, and these cells are 100% double 
positive for polymodification and CD42b+. (E) All proplatelet extensions observed are positive for polymodification. (F) 
Polyglutamylation and polyglycylation are evident by western blotting in mature iPSC-MKs derived from 3 separate 
differentiations. (G) iPSC were transfected with a TUBB1 targeting guide RNA, after which indel positive cells were 
isolated and sequenced to positively identify a bi-allelic insertion-deletion mutant (clone T2). (H) This clone was further 
analyzed and loss of β1-tubulin expression was confirmed by qRT-PCR. (I,J) A comparison of proplatelet production in 
wild-type vs. TUBB1 KO cells revealed a complete loss of proplatelet formation in mutant CD41/42b+ cells. (K) TUBB1 
knock-out clones show a disordered arrangement of polymodified residues when compared to WT cells. KO cells do 
not demonstrate the re-organisation of tubulin to the periphery of the cell evident in WT iPSC-MKs (indicated by red 
arrows). (L) A measure of the polyglutamylation and polyglycylation in WT vs. KO clones reveals a significant increase 
in polyglycylation in mutant cells consistent with an aberrant accumulation of these residues. (n = 3 independent 
differentiations, S.D. plotted on graphs) 
 
Figure 4. Platelet activation results in polyglutamylation of the marginal band (A) Resting platelets show a partial 
polyglutamylation of the marginal band and a loss of the polyglycylation evident in iPSC-MKs. (B) Platelet spreading 
on fibrinogen and collagen shows an accumulation of polyglutamylation at the marginal band as platelets spread, and 
no evidence of polyglycylation. (C) Western blotting of resting and CRP activated platelets confirms the presence of 
polyglutamylated tubulin and a loss of polyglyclation. No increase in polyglutamylation is evident over time. (D) A 
measurement of co-localisation (corrected Manders coefficient) between polyglutamylated tubulin and β1-tubulin in 
resting and spread platelets shows a significant increase in the co-localisation of these modified tubulin residues on 
platelet activation and spreading. (E) Platelets activated in vitro using CRP were fixed and co-stained for β1-tubulin 
and polyglutamylated residues, and then imaged in 3D using AiryScan confocal (stacks colourized in Z as indicated by 
the colour chart in this figure). In these micro-thrombi, polyglutamylation of the marginal band is evident, while 
polyglycylation is not observed. (F) A time course was performed to compare polyglutamylated tubulin with two other 
previously reported PTMs in platelets (acetylation and tyrosination). Polyglutamylation is maintained over time, while 
acetylation and tyrosination decrease significantly as platelets spread. (G) The mean fluorescence intensity of 
polyglutamylated tubulin is markedly higher than either acetylated or tyrosinated tubulin. (n = 3, S.D., Two-Way 
ANOVA with multiple comparisons. 10 µm scale bar.) 
 
Figure 5. Polyglutamylation regulates spatial distribution of motor proteins in platelets and MKs. (A, B) Quantification 
of the co-localisation of dynein, as measured by the corrected Manders coefficient, with polyglutamylated tubulin over 
time shows a marked decrease in co-localisation between these polymodified residues and the motor over time. (C) In 
fibrinogen and collagen spread cells, dynein is observed on the periphery of the spread cells, (D) while kinesin-1 is 
evident as a diffuse punctate stain. (E) Dynein co-localisation with polyglutamylated residues decreases dramatically 
on platelet spreading in both fibrinogen and collagen (** p = 0.0082 and p = *** 0.0004 respectively). (F) a loss of co-
localisation with polyglutamylated tubulin is evident in fibrinogen and collagen spread cells (** p = 0.0017, **** p < 
0.0001 respectively). (G) Immunofluorescence staining of iPSC-MKs for polymodified tubulin, dynein, and kinesin-1 
show the distribution of both motors along the length of the proplatelet shaft in WT cells. (H, I) In β1-tubulin knock-out 
iPSC-MKs, no proplatelet extensions are formed and a significant reduction in the co-localisation of dynein to 
polyglutamlated residues is observed (* p = 0.0166 and * p = 0.0293 respectively), (J) with no significant change in the 
co-localisation of kinesin-1 with polyglycylated tubulin. (n = 3, S.D., Two-Way ANOVA with multiple comparisons.) 
 
(G) Figure 6. iPSC-MKs and platelets differentially express TTLL and CCP enzymes to regulate polymodifications 
during MK maturation and platelet production. The loss of TTLL10 is possibly linked to a bleeding phenotype in 
unrelated human patients. (A) RNA was generated from iPSC-MKs at different stages of terminal differentiation. Day 1 
(d1) day 5 (d5) day 5 cells treated with heparin to induce proplatelet formation (d5 + Hep) were used to determine 
whether an upregulation of these enzymes is evident on platelet production. (B) Samples were amplified with 
housekeeping GAPDH primers (C) A number of TTLL family enzymes were observed, including TTLLs1, 2, 3, 4, 5, 6, 
7, 10, and 13. Of these, a number appeared to be up-regulated in mature and proplatelet forming cells. (D, E) These 
samples were taken forward and expression was quantified over multiple differentiations using the ΔΔCT method TTLL 
1, 2, 4, and 10 expression was found to be significantly upregulated on treatment with heparin (** p = 0.0081, * p = 
0.0105, * p = 0.0260, *** p = 0.0004 respectively). (F, G, H) A similar panel was performed on CCP enzymes which 
reverse polymodifications, with expression of CCP1, 3, 4, 5, and 6 was observed. Statistically significant upregulation 
of CCPs 4, and 6 were observed on proplatelet production (* p = 0.0130, *** p = 0.0009). (I) In resting (-) and CRP 
activated (+) platelets from 3 healthy donors TTLL7 was the only modifying enzyme found to be consistently 
expressed. (J) Three unrelated families were identified within the GAPP cohort, two with frameshift truncations and 
one with a missense substitution (p.Pro15Argfs*38, p.Val249Glyfs*57, and p.Arg340Trp respectively). (K) All three 
families present with normal platelet counts and function, but demonstrate an elevated mean platelet volume (MPV) 
and consistent histories of bleeding including cutaneous bruising and menorrhagia. (L) Patient A:1:1 was recalled and 
demonstrated abnormally large platelets on spreading on fibrinogen when imaged by widefield and single molecule 
localisation microscopy (tubulin staining, 10 µm scale bar, 5 µm in cropped image). (n = 3, S.D., Two-Way ANOVA 
with multiple comparisons performed. Complete unedited gels found in figures S9, S10.) 
 
Figure 7. A system of competitive polymodification of TUBB1 driven by the expression of TTLL and CCP enzymes is 
required for platelet production and function. We observe a system by which as iPSC-MKs mature and express 
TUBB1, they acquire both polyglutamylated and polyglycylated tubulin which co-incides with an increase in the 
expression of glutamylating and glycylating TTLLs and reversing CCPs. A resting platelet is partially polyglutamylated, 
and on activation the marginal band is further polyglutamylated to drive shape change and spreading through the 
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1 
Supplementary Materials and Methods 
Whole exome sequencing (WES). 
To identify the causative mutation in these families we sequenced the whole exome of the affected 
individuals with the SureSelect human AllExon 50 Mb kit (Agilent Technologies) and sequenced on the 
HiSeq 2500 (Illumina) with 100 bp paired-end reads. The sequences were aligned to the reference 
genome (hg19 build), with Novoalign (Novocraft Technologies Sdn Bhd). Duplicate reads, resulting from 
PCR clonality or optical duplicates, and reads mapping to multiple locations were excluded from 
downstream analysis. Depth and breadth of sequence coverage was calculated with custom scripts and 
the BedTools package. Single nucleotide substitutions and small insertion deletions were identified and 
quality filtered within the SamTools software package and in-house software tools. All calls with a read 
coverage <4 and a phred-scaled SNP quality of <20 were filtered out. Genetic variants were annotated 
with respect to genes and transcripts with the Annovar tool. Candidate variants were prioritised 
according to their frequency in the latest population databases where a rare variant was defined as 
<0.01. 
Platelet preparation. 
25 mL volumes of blood were drawn from volunteers into sodium citrate. PRP (platelet-rich plasma) 
was generated by centrifugation of samples for 20 minutes at 200 g. PRP was further spun to isolate 
platelets by centrifugation at 1,000 g for 10 minutes with prostacyclin (0.1 µg/mL) and ACD. The 
resulting pellet was suspended in Tyrode’s buffer prepared fresh, and pre-warmed at 37°C (5 mM 
glucose, 1 mM MgCl2, 20 mM HEPES, 12 mM NaHCO3, 2.9 mM KCL, 0.34 mM Na2HpO4, 129 mM 
NaCl to a pH of 7.3). This suspension was spun again at 1,000 g with prostacyclin at the same 
concentration before being re-suspended to a final concentration of 2 x 108/mL. Platelets were left to 
rest for 30 minutes at room temperature before any further processing or treatment. 
Platelet spreading.  
Resting platelets were fixed by preparing platelets at a concentration of 4 x 107/mL and mixing with 
equal volumes of 10% neutral buffered Formalin in a 15 mL falcon tube. This mixture was inverted 
gently to mix the sample, and left to incubate for 5 minutes before subsequently adding 300 µL of the 
resulting fixed, resting platelets to coverslips coated in Poly-L-Lysine (Sigma). Cells were then spun 
down at 200 g for 10 minutes. 
Spreading was performed on human fibrinogen (Plasminogen, von Willebrand Factor and Fibronectin 
depleted - Enzyme Research Laboratories) and Horm collagen (Takeda). Coverslips were coated 
overnight at a concentration of 100 µg and 10 µg/mL (fibrinogen and collagen) respectively, before 
blocking for 1 hour in denatured fatty acid free 1% BSA (Life Technologies). Finally coverslips were 
washed once with PBS before the addition of platelets. Unless otherwise stated (as in the time course 
experiment), platelets were spread for 45 minutes at 37°C. Fixation for spread platelets was performed 
in formalin as for resting platelets for 10 minutes. 
2 
Construct cloning and transfection. 
β1-tubulin WT construct was generated by the gibson assembly (HiFi Kit, New England Biolabs) of a 
TubB1 sequence fragment synthesised as a gBlock by Integrated DNA Technologies (IDT) and a C-
terminal mApple empty backbone (mApple-C1 was a gift from Michael Davidson (Addgene plasmid 
#54631; http://n2t.net/addgene:54631 ; RRID:Addgene_54631)41. All mutagenesis experiments were 
performed using the Q5 site directed mutagenesis kit from New England Biolabs following their 
supplied protocol. The table in supplementary figure S2 provides the primers and annealing 
temperatures used to produce the various mutants using the mAPPLE TubB1 plasmid as a template. 
All primers were designed using the online NEBase changer tool. Transfection was performed using 
a standard Lipofectamine 3000 protocol in Hek293T cells maintained in complete DMEM as 
described in the author’s previous work42,43. 
Immunofluorescence.  
After fixation platelets were washed twice with PBS before incubation in 0.1% Triton X-100 for 
5 minutes. The subsequently permeabilised cells were washed twice with PBS before blocking in 
2% Goat serum (Life Technologies) and 1% BSA (Sigma). Fixed, permeablised, and blocked cells 
were then incubated with primary antibodies at a concentration of 1:500 unless other-wise 
stated. The following antibodies were used for experiments in this work: polyglutamylated 
tubulin (mouse monoclonal antibody, clone B3 T9822, Sigma), pan-polyglycylated antibody 
(mouse monoclonal antibody, AXO49, MABS276 Millipore), monoglycylated antibody (AXO 
962 mouse monoclonal MABS277, EMD Millipore), kinesin-1 (rabbit monoclonal to KIF1B ab 
167429, abcam), axonemal dynein, b1-tubulin (Rabbit polyclonal PA5-16863), tyrosinated tubulin 
(rabbit monoclonal antibody, clone YL1/2, MAB1864, EMD Millipore), acetylated tubulin (Lys40, 
6-11B-1, mouse monoclonal antibody, Cell Signalling Technology) and DNAI1 antibody (PA5-30643
Invitrogen).
After a 1 hour incubation in the relevant mix of primary antibodies. Cells were washed twice with
PBS before incubation in secondary antibodies (Alexa-568-phalloidin, anti-rabbit Alexa-647, anti-
mouse Alexa-588 (Life Technologies) for one hour at a dilution of 1:300 in PBS.
Stem Cell Culture.
Gibco human episomal induced pluripotent stem cell line was purchased from Thermo Scientific 
and cultured on Geltrex basement membrane in StemFlex medium (Thermo Scientific). Routine 
passaging was performed using EDTA (Sigma), with single cell seeding performed for transfection 
and attempted clonal isolation through the use of TrypLE (Thermo Scientific). Briefly, cells were 
washed twice with PBS and once with either EDTA (for clump passaging) or TrypLE (for single cell) 
before incubation in 1 mL relevant detachment media for 3 minutes at 37°C. For clump passaging, 
EDTA was removed and 1 mL of StemFlex added. Cells were detached by triturating media onto 
the bottom of the well and subsequently adding the required volume to fresh media (in a new, 
Geltrex coated plate). For single cell seeding, TrypLE was diluted in 2 mL StemFlex and the 
solution added to a 15 mL falcon tube for centrifugation at 200 g for 4 minutes. The supernatant 
was then discarded and the cell pellet resuspended in the required volume. 
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iPSC MK differentiation. 
iPSC differentiation to mature, proplatelet forming megakaryocytes was performed using a protocol 
based on work published by Feng et al.23. To summarise, cells were detached by clump passaging 
and seeded on dishes coated with Collagen Type IV (Advanced Biomatrix) at 5 µg. Cells were 
seeded overnight with RevitaCell (Life Technologies) to support survival on the new basement 
substrate. To begin the protocol cells were washed twice and incubated in phase I medium 
comprised of APELII medium (Stem Cell Technologies) supplemented with BMP-4 (Thermo 
Scientific), FGF2-β, and VEGF (Stem Cell Technologies) at 50 ng/mL each. Cells were incubated at 
5% oxygen for the first four days of the protocol before being placed in a standard cell culture 
incubator for a further two days in freshly made phase I medium. At day 6 of the protocol cells were 
incubated in phase II media comprised of APELII, TPO (25 ng/mL), SCF (25 ng/mL), Flt-3 (25 ng/
mL), Interleukin-3 (10 ng/mL), Interleukin-6 (10 ng/mL) and Heparin (5 U/mL) (all supplied by Stem 
Cell Technologies). Each day in phase II media suspension cells were spun down at 400 g for 5 
minutes and frozen in 10% FBS/DMSO. After 5 days of collection, all frozen cells were thawed for 
terminal differentiation. Terminal differentiation was performed by incubating cells in StemSpan II 
with heparin (5 U/mL) and Stem Cell Technologies Megakaryocyte Expansion supplement on low 
attachment dishes (Corning). 
RNP Complexes.
The IDT Alt-R®RNP system was used to target and knock-out TUBB1. crRNAs were ordered at 2 
nmol and resuspended in 20 µL TE buffer (IDT) for a final concentration of 100 µM. Atto-555 
labelled tracrRNAs were ordered at 5 nmol and resuspended in a volume of 50 µL for a final 
concentration of 100 µM. To prepare small guide RNAs (sgRNA), equimolar ratios of both crRNA 
and tracrRNA were mixed with Nuclease Free Duplex Buffer (IDT). This mix was then incubated 
at 95°C for 5 minutes before allowing the reaction mix to cool at -1°C/second to 25°C. This mix 
was then spun down and complexed with HiFi Cas9 V3 (1081058 - IDT) purified Alt-R®. Cas9 
protein was diluted to 6 µg per transfection and incubated with an equal volume of annealed 
sgRNA. This mix was left for 30 minutes at room temperature to form complete and stable RNP 
complexes. 
Stem Cell Transfection.
iPSC transfection was performed using Lipofectamine Stem (Life Technologies) according 
to manufacturer instructions. Briefly, iPSC were seeded on 24 well dishes coated with Geltrex at 
50,000 cells per well. After an overnight incubation in StemFlex with RevitaCell, cells were washed 
twice with PBS and once with OptiMem before incubation in OptiMem with RevitaCell. RNP 
complexes were prepared as described in section and resuspended in 25 µL OptiMem per 
reaction. A Lipofectamine Stem master mix was prepared using 25 µL OptiMem and 2 µL 
Lipofectamine STEM per reaction (4 µL if a donor template is included). Equal volumes of both 
Lipofectamine and RNP mix were incubated to form lipofection complexes over a 10 minute 
incubation at room temperature. The final transfection mix was added to cells in OptiMem and left 
for 4 hours before the addition of StemFlex medium (and any relevant small molecules). 
Measurement of iPSC transfection efficiency after treatment with Lipofectamine STEM and IDT 
RNP complexes was performed using manual cell counting in Evos acquired images (Phase 
contrast and fluorescence). 
Microscopy. 
Images were acquired using an Axio Observer 7 inverted epifluorescence microscope (Carl Zeiss) 
with Definite Focus 2 autofocus, 63x 1.4 NA oil immersion objective lens, Colibri 7 LED illumination 
source, Hammamatsu Flash 4 V2 sCMOS camera, Filter sets 38, 45HQ and 50 for Alexa488, 
Alexa568 and Alexa647 respectively and DIC optics. LED power and exposure time were chosen 
as appropriate for each set of samples but kept the same within each experiment. Using Zen 2.3 Pro 
software, five images were taken per replicate, either as individual planes (spread platelets) 
or representative Z-stacks (resting platelets). Images were prepared for presentation using Fiji 
(ImageJ). LUTs were adjusted for presentation purposes, and a rolling ball background subtraction 
applied. Where Z-stacks are taken, images are presented as a maximum intensity 
projection. Hek293T cells were imaged using an AiryScan confocal microscope as detailed in 
Smith et al.44 dSTORM imaging of TTLL10 patient and control samples was performed as 
described by Khan et al.42,43 applying dSTORM and ThunderSTORM reconstruction to samples 
labelled with AlexaFluor 647 in the presence of a blinking buffer. 
Image analysis.
Image analysis of resting and spread platelets was performed using a customised workflow 
published by Pike et al45. Briefly, the actin channel from resting and spread platelet images 
was used to train Ilastik pixel classifiers (approximately 6 images per condition) for segmentation 
based on this channel as described by Pike et al.. This was incorporated into a KNIME 
workflow which would run images through the classifier to generated segmented binaries in 
which co-localisation and fluorescence intensity statistics were calculated46–48. For the data 
presented in this manuscript, M1diff (a corrected Mander’s co-efficient to channel 1) was used to 
determine the co-localisation of PTMs to tubulin, and an M2dif f value (corrected Mander’s co-
efficient to channel 2) was used to calculate the co-localisation of motor proteins to PTMs of 
interest49. MKs and Hek293T were segmented manually by drawing a region of interest around 
cells in a projected Z-stack image. For co-localisation, these images were then fed through the same 
automated analysis pipeline as the platelet data45 for co-localisation values. For measures of 
intensity in Hek293T images, cells were manually segmented (an ROI drawn) and 
fluorescence values in polyglutamylated and polyglycylated channels were subsequently measured and 
normalised to account for variation in transfection efficiency.
Quantitative Real Time PCR (qRT-PCR).
To determine whether the 13 mammalian TTLLs and 6 CCPs were expressed in iPSC-MKs at 
the different stages of differentiation (day 1, day 5 and day 5 +heparin) a qRT-PCR panel was 
developed using TaqMan technology and an ABI 7900 HT analyser (Applied Biosystems, 
Warrington, UK). RNA samples were isolated and reverse-transcribed and amplified with the 
relevant primers using SYBR-Green based technology (Power SYBR(r) Master Mix, Life 
Technologies). Total RNA was extracted from iPSC cells using the NucleoSpin RNA kit (Machery-
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Nagel) and cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Life 
Technologies). qRT-PCR was performed on all the TTLL/CCP fragments generated from 
primers designed in supplementary figure 5 and the housekeeping control GAPDH 
(GAPDHFOR 5’-GAAGGTGAAGGTCGGAGT-3’ and GAPDHREV 5’-
GAAGATGGTGATGGGATTTC-3’). Each reaction was set up in triplicate including a non-
template control. Expression was analysed using the CT method using D1 undifferentiated cells as a 
control. A full list of primer sequences can be found in figure S8. 
Supplementary Figures and Tables
1
Fig. S1. Patient flow cytometry data reveals secondary defects. The GAPP project collects phenotypic data on patient recruit-
ment, allowing for the assessment of secondary defects through FACS screening. (A) Individuals from family A show a reduction 
in P-selectin at both concentrations of CRP, and low concentration PAR-1. (B) Patients similarly show a reduction in fibrinogen up-
take compared to controls, but show no difference in (C) surface marker expression. (D) Patient B shows a marked reduction in 
P-selectin surface expression and (E) fibrinogen uptake compared to controls. Platelet surface receptor normal range values (from 
healthy volunteers) - Blank –190 (SD 27); isotype control - 637 (SD 208); CD41 – 28727 (15378); CD42b – 10318 (SD 4257); 
GPVI – 5693 (SD 2447). P-selectin mean responses (Neat PRP) : Blank – 485 (SD 132); ADP 3 µm – 1261 (SD 558); ADP 30 
µm – 2575 (SD 742). CRP 0.3 µg/mL– 4076 (SD 2297); CRP 3.0 µg/mL – 8177 (SD 1781). PAR-1 10 µM – 1636 (SD 1118); 
PAR-1 100 µM – 6642 (SD 1211). Fibrinogen mean responses (Neat PRP) : Blank – 2442 (SD 1253); ADP 3 µm – 95756 (SD 
57434); ADP 30 µm – 137242 (SD 99347). CRP 0.3 µg/mL– 35095 (SD 62454); CRP 3.0 µg/mL – 94905 (SD 63054). PAR-1 
10 µM – 81794 (SD 75990); PAR-1 100 µM – 89744 (SD 54673). (F) Sanger sequencing of patient samples from Family A. (G) 
WES analysis and subsequent genetic variant interpretation in Family A. This was performed using the clinical variant interpreta-
tion platform Congenica https://www.congenica.com) and candidate genes were filtered and selected based on an Inherited bleed-ing 
Disorder (IBD)-specific panel of 119 genes29. The following rare variants were found collectively within the different individuals of family 
A (AN06 - ENST00000435642.1:c.1165+21delT, COL5A1 - NM_000093.4:c.4760T>G, NP_000084.3:p.Ile1587Ser, F13A1
- NM_000129.3:c.-18-7dupT, GFI1B - NM_004188.4:c.503G>T, NP_004179.3:p.Cys168Phe, HABP2 - NM_004132.3:c.1046G>A, 
NP_004123.1:p.Gly349Glu, TUBB1 - NM_030773.3:c.1075C>T, NP_110400.1:p.Arg359Trp, SMAD4 - NM_005359.5:c.-127-1G>T, 
STIM1 - NM_003156.3:c.974G>A, NP_003147.2:p.Arg325Gln). Individuals and their variants with a low platelet count are shown 
in red font where only GFI1B and TUBB1 variants are common to both individuals.(H) Clinical and laboratory interpretation of 
the GFI1B and TUBB1 variants found in individuals of family A. In silico prediction tools tools used were as follows (POLYPHEN 
http://genetics.bwh.harvard.edu/pph2/; SIFT https://sift.bii.a-star.edu.sg; Align GVGD http://agvgd.hci.utah.edu/agvgd_input.php). 
Population frequencies were obtained from the genome aggregation database (Gnomad https://gnomad.broadinstitute.org). Current 
ACMG guidelines are used as supporting evidence; PP1: co-segregation with disease in multiple affected family members in a gene 
definitively known to cause the disease; PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene 
product (conservation, evolutionary, splicing impact, etc.)
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Fig. S2. Generation of WT and mutated mApple-—1-tubulin plasmids. (A) An N-terminal mApple-—1 tubulin over expression vector
was designed and cloned through the gibson assembly of the —1 tubulin sequence into a C-terminal mApple construct (mApple-C1 was
a gift from Michael Davidson (Addgene plasmid # 54631 ; http://n2t.net/addgene:54631 ; RRID:Addgene_54631). Of the 6 selected
clones presented, clone 6 demonstrated cleavage bands of the predicted molecular weight, and was subsequently cloned. (B) The
correctly assembled sequence was then transfected to and co-stained with a —-tubulin antibody to confirm the correct expression and
fold of this tubulin construct. (C) Mutants of the WT construct were generated through a Q5 site directed mutagenesis kit to generate
constructs harbouring patient RW and G insertion mutants, as well as an artificially designed C-terminus truncation of the protein. (D)
Primers used for the site directed mutagenesis are listed with their respective annealing temperatures.
Fig. S3. Western blotting of TubB1 mutant constructs. Mutant TubB1 constructs were re-cloned without the mApple label and
transfected into Hek293T. Transfected cells were then collected and lysed for western blotting. (A) A reduction in polyglutamylation
and polyglycylation is evident when compared to wild type TubB1 constructs. (B) Polyglutamylation was significantly reduced in RW,
G insert, and C terminal truncations (* p = 0.0102, ** p = 0.0011, ** p = 0.0017), as was polyglycylation (* p = 0.0210, 0.0434, p =
0.0338.).
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Fig. S4. Directed differentiation of iPSC to proplatelet forming MKs. (A) A 3 stage protocol was adapted from a method previously
published by Feng et al.. Briefly, iPSC were clump passaged on to collagen IV coated plates and incubated in RevitaCell overnight
before beginning Phase I of the differentiation. Phase I involves a 4 day incubation at 5% O2 in APEL2 media supplemented with 50ng
of BMP4, VEGF, and FGF2, after which fresh media was added and cells were incubated for 2 more days at normoxic conditions.
Phase II of the protocol involved incubation in APEL2 supplemented with IL3, IL6, Flt-3, hSCF, TPO, heparin, during which time cells
were harvested and frozen every 48 hours and fresh media added. Finally, harvested cells were thawed and incubated in StemSpan II
medium with MK supplement for 5 days before samples were prepared for downstream assays (immunofluorescence, RT-PCR etc.). (B)
During Phase II of the differentiation, progressively larger numbers of blast like cells are observed emerging from a layer of haemogenic
endothelium. (C) During Phase III of the differentiation, cells grow from progenitors and blast like cells approximately 10 µm in size to
large, mature MKs ranging in 25-40 µm in size. (D) At day 5, on treatment with Y-27632 and heparin, cells form elaborate proplatelet
networks. (E) 60% of terminally (Phase III) differentiated cells are CD41 and CD42 double positive and on staining demonstrate (F,G)
a mix of ploidies and proplatelet networks consistent with mature platelet producing MKs.
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Fig. S5. CRISPR bi-allelic knock-out of —1 tubulin. (A) Guides targeting exon 1 of the TUBB1 gene were designed and (B) tested for
efficiency using a T7EI cleavage assay. The population evidencing the most cleavage (and hence most efficient guide (guide A)) was
taken forward to generate TUBB1 knock-out clones, through single cell clonal isolation. (C) Cells positive for cleavage on single cell
expansion (identified by the red arrows) were taken forward for sequencing. (D) Clone T2 revealed a bi allelic loss of the start codon,
(E) resuling in a deletion of a significant portion of the N-terminus and as evidenced in the main text, a loss of TUBB1 expression.
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Fig. S6. Staining of Cytoplasmic Dynein in resting and Spread Platelets. Resting and spread human donor platelets were stained
for cytoplasmic dynein to compare the distribution of this isoform of the motor protein to axonemal dynein. While axonemal dynein is
primarily found on the edge of spreading cells, cytoplasmic dynein is found at the centre of spread cells, suggesting that the axonemal
variant is involved in platelet spreading and activation.
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Fig. S7. Line profiles demonstrating difference in distribution of polymodified tubulin in knock-out cells. Line profiles demon-
strating the different distribution of polymodified residues in wild type vs. knock-out iPSC MK. In wild type cells, both polymodifications
accumulate around the periphery of mature cells forming a dense microtubule band indicated by distinctive peaks on their respective
line profiles (B). In contrast, knock-out cells have a disordered and diffuse distribution of tubulin indicated by their line profiles.
Fig. S8. Primers and predicted fragment lengths for qRT-PCR screen of TTLL and CCP expression. Exon overlapping primers
were disgned for a qRT-PCR screen of TTLL and CCP expression. Forward and reverse primer sequences are listed, along with
predicted fragment length.
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Fig. S9. Whole gel for TTLL and CCP RT-PCR screen in iPSC-MKs. Complete gels used in figure 6.
Fig. S10. Whole gel for TTLL10 and CCP RT-PCR screen in human peripheral blood platelets. Complete platelet gel used in
figure 6.
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Fig. S11. Resting platelets co-stained for dynein and kinesin. Resting platelets co-stained for kinesin and dynein to supplement
spread figures.
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Fig. S12. Rare and novel TTLL10 genetic variants identified in WES data from affected individuals. Variants were filtered;
synonymous variants and variants with a minor allele frequency (MAF) were excluded, and non-shared variants. The pathogenicity of
the remaining variants was predicted using tools (Mutation Taster, Phastcons, SIFT, Provean etc.) and American College of Medical
Genetics and Genomics (ACMG) classification Candidate variants are selected on the basis of a pathogenic prediction. Supporting
evidence is given where PM2 is “Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000
Genomes Project, or Exome Aggregation Consortium”, PP3 is “Multiple lines of computational evidence support a deleterious effect on
the gene or gene product (conservation, evolutionary, splicing impact, etc.)” and PM4 is “Protein length changes as a result of in-frame
deletions/insertions in a non-repeat region or stop-loss variants”. 10
Fig. S13. Supplementary figure 13 Sanger sequencing of the TTLL10 variants for confirmation following WES. Representative
confirmative Sanger sequencing electropherograms are shown. Black arrow shows sites of genomic variation. A) c.462delG. B)
c.745_746insG. Reference sequence- NM_001130045.
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